Rare genetic diseases of the bone tissue: the case of a family with osteogenesis imperfecta and X-linked hypophosphataemia

Osteogenesis imperfecta (OI) and X-linked hypophosphataemia (XLH) are rare genetic diseases, which lead to childhood-onset bone fragility, low-trauma fractures and limb deformities. OI occurs as a result of impaired type 1 collagen synthesis at different stages, depending on the type of a genetic mutation, which leads to bone strength impairment. In most cases OI is a disorder with an autosomal dominant inheritance. However, there are also cases of autosomal recessive inheritance. To date, 16 types of OI are distinguished, with type 2 being the most severe due to 100% mortality rate in neonatal and perinatal periods. XLH is characterized by altered bone mineralization due to impaired phosphorus absorption and reabsorption, as a result of mutations in the PHEX gene. The bone tissue «softens», and this process is accompanied by deformities in long tubular bones. In this article we describe the family, in which both diseases are presented, despite their rarity. The case is investigated from points of view: the clinician’s and the patient’s perspective.

1. Forlino A, Marini JC. Osteogenesis imperfecta. The Lancet. 2016;387(10028):1657-1671. doi: 10.1016/s0140-6736(15)00728-x

2. Forlino A, Cabral WA, Barnes AM, Marini JC. New perspectives on osteogenesis imperfecta. Nat Rev Endocrinol. 2011;7(9):540-57. doi: 10.1038/nrendo.2011.81

3. Bacon S, Crowley R. Developments in rare bone diseases and mineral disorders. Ther. Adv Chronic Dis. 2017;9(1):51-60. doi: 10.1177/2040622317739538

4. Bergwitz C, Jüppner H. Regulation of Phosphate Homeostasis by PTH, Vitamin D, and FGF23. Annu Rev Med. 2010;61(1):91-104. doi: 10.1146/annurev.med.051308.111339

5. Куликова К.С., Колодкина А.А., Васильев Е.В., и др. Клинические, гормонально-биохимические и молекулярно-генетические характеристики у 75 пациентов с гипофосфатемическим рахитом // Проблемы Эндокринологии. - 2016. - Т. 62. - №2. - C. 31-36. [Kulikova KS, Kolodkina AA, Vasiliev EV, et al. Clinical, hormonal, biochemical and genetic characteristics of 75 patients with hypophosphatemic rickets. Problems of Endocrinology. 2016;62(2):31. (In Russ).] doi: 10.14341/probl201662231-36

6. Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е., и др. Клинические рекомендации Российской ассоциации эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. // Проблемы эндокринологии. - 2016. - Т. 62. - №4. - С. 60-84. [Pigarova EA, Rozhinskaya LY, Belaya JE, et al. Russian Association of Endocrinologists recommendations for diagnosis, treatment and prevention of vitamin D deficiency in adults. Problems of Endocrinology. 2016;62(4):60. (In Russ).] doi: 10.14341/probl201662460-84

7. Martin E, Shapiro JR. Osteogenesis imperfecta: Epidemiology and pathophysiology. Current Osteoporosis Reports. 2009;5(3):91-97. doi: 10.1007/s11914-007-0023-z

8. Войтович Т.Н., Баранаева Е.А., Безлер Ж.А., Чанчикова М.В. Несовершенный остеогенез. // Медицинский журнал. - 2009. – Т. 28. - №2. - С. 138-140. [Vojtovich TN, Baranaeva EA, Bezler ZhA, Chanchikova MV. Nesovershennyj osteogenez. Medicinskij zhurnal. 2009;28(2):60-84 (In Russ).]

9. Van Dijk FS, Sillence DO. Osteogenesis imperfecta: Clinical diagnosis, nomenclature and severity assessment. Am J Med Genet A. 2014;164(6):1470-1481. doi: 10.1002/ajmg.a.36545

10. Vuorimies I, Mäyränpää MK, Valta H, et al. Bisphosphonate Treatment and the Characteristics of Femoral Fractures in Children With Osteogenesis Imperfecta. J Clin Endocr Metab. 2017;102(4):1333-1339. doi: 10.1210/jc.2016-3745

11. Hennedige AA, Jayasinghe J, Khajeh J, Macfarlane TV. Systematic Review on the Incidence of Bisphosphonate Related Osteonecrosis of the Jaw in Children Diagnosed with Osteogenesis Imperfecta. J Oral Maxillofac Res. 2013;4(4). doi: 10.5037/jomr.2013.4401

12. Hoyer-Kuhn H, Franklin J, Allo G, et al. Safety and efficacy of denosumab in children with osteogenesis imperfecta - a first prospective trial. J Musculoskelet Neuronal Interact. 2016; 16(1):24–32

13. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., и др. Федеральные клинические рекомендации по диагностике, лечению и про филактике остеопороза // Проблемы эндокринологии. - 2017. - Т. 63. - №6. - С. 392-426. [Melnichenko GA, Belaya ZE, Rozhinskaya LY, et al. Russian federal clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis. Problems of Endocrinology. 2018;63(6):392-426. (In Russ).] doi: 10.14341/probl2017636392-426

14. Orwoll ES, Shapiro J, Veith S, et al. Evaluation of teriparatide treatment in adults with osteogenesis imperfecta. J Clin Invest. 2014;124(2):491-498. doi: 10.1172/jci71101

15. Vahle JL, Sato M, Long GG, et al. Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety. Toxicol Pathol. 2016;30(3):312-321. doi: 10.1080/01926230252929882

16. Белая Ж.Е., Рожинская Л.Я. Анаболическая терапия остеопороза: эффективность, безопасность и область применения // Остеопороз и остеопатии. - 2013. – Т.16. - №2. - С. 32-40. [Belaya ZE, RozhInskaya LY. Anabolicheskaya terapiya osteoporoza. Teripaparatid: effektivnost', bezopasnost' i oblast' primeneniya. Osteoporosis and bone diseases. 2013;16(2):32-40. (In Russ).] doi: 10.14341/osteo2013232-40

17. Crowley RK, Kilbane M, King TFJ, et al. Hungry bone syndrome and normalisation of renal phosphorus threshold after total parathyroidectomy for tertiary hyperparathyroidism in X-linked hypophosphataemia: a case report. J Med Case Reports. 2014;8(1). doi: 10.1186/1752-1947-8-84

18. Imel EA, Zhang X, Ruppe MD, et al. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23. J Clin Endocr Metab. 2015;100(7):2565-2573. doi: 10.1210/jc.2015-1551

19. Aono Y, Yamazaki Y, Yasutake J, et al. Therapeutic Effects of Anti-FGF23 Antibodies in Hypophosphatemic Rickets/Osteomalacia*. J Bone Miner Res. 2009;24(11):1879-1888. doi: 10.1359/jbmr.090509.